Year: 2019
Type: review
Abstract: Studies about the pathogenesis of mood disorders have consistently shown that multiple factors, including genetic and environmental, play a crucial role on their development and neurobiology. Multiple pathological theories have been proposed, of which several ultimately affects or is a consequence of dysfunction in brain neuroplasticity and homeostatic mechanisms. However, current clinical available pharmacological intervention, which is predominantly monoamine-based, suffers from a partial and lacking response even after weeks of continuous treatment. These issues raise the need for better understanding of aetiologies and brain abnormalities in depression, as well as developing novel treatment strategies. Nitric oxide (NO) is a gaseous unconventional neurotransmitter, which regulates and governs several important physiological functions in the central nervous system, including processes, which can be associated with the development of mood disorders. This review will present general aspects of the NO system in depression, highlighting potential targets that may be utilized and further explored as novel therapeutic targets in the future pharmacotherapy of depression. In particular, the review will link the importance of neuroplasticity mechanisms governed by NO to a possible molecular basis for the antidepressant effects.
Source: Cell and Tissue Research
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,760
Funders: Aarhus Universitet, Sundhed og Sygdom, Det Frie Forskningsråd, Fundação de Amparo à Pesquisa do Estado de São Paulo, Aarhus Universitets Forskningsfond, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Bureau of Reclamation, Aarhus Institute of Advanced Studies, Aarhus Universitet, Instituto Nacional de Ciência e Tecnologia da Criosfera, H2020 Marie Skłodowska-Curie Actions
Awards: G6207894495, G6387845645, G7277057726
OpenAlex ID: W2909163875
